Sfoglia per AUTORE
ORLOV SV
Collezione AOU San Luigi di Orbassano
Items : 1
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. in ESMO open / ESMO Open. 2020 Jan;5(1):e000567. doi: 10.1136/esmoopen-2019-000567.
2020
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Lee P; Wolff K; Alexandris E; Oton AB; Zimmermann AH; Orlov SV; Cuyun Carter G; Brustugun OT; Gans S; Kim JH; Kalofonos H; Iglesias Docampo L; Thomas M; Reck M; Gautschi O; Scagliotti GV; Garon EB; Stefaniak VJ; Socinski MA; Pérol M;